Candida Auris MIC Testing by EUCAST and Clinical and Laboratory Standards Institute Broth Microdilution, and Gradient Diffusion Strips; to Be or Not to Be Amphotericin B Resistant?

Details

• Alternative Title:
  Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025, v. 31, no. 1: Candida Auris MIC Testing by EUCAST and Clinical and Laboratory Standards Institute Broth Microdilution, and Gradient Diffusion Strips; to Be or Not to Be Amphotericin B Resistant?
• Journal Article:
  Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
• Personal Author:
  Arendrup, Maiken Cavling ; Lockhart, Shawn R. ; Wiederhold, Nathan
• Description:
  Reported amphotericin B resistance rates for Candida auris vary considerably. This may reflect clinically relevant differences in susceptibility, technical issues with testing, or adoption of a clinical breakpoint that bisects the wild-type population. We compared reference methods and two gradient diffusion strips using a shared C. auris strain collection.
  
  Forty C. auris strains from nine U.S. states and ≥3 clades were included. Fourteen MIC data sets were generated using European Committee on Antimicrobial Susceptibility Testing (EUCAST) E.Def 7.4, Clinical and Laboratory Standards Institute (CLSI) M27Ed4, Etest, and MIC gradient test strip (MTS, Liofilchem) MICs. MICs ≤1 mg/L were classified as susceptible.
  
  EUCAST and CLSI amphotericin B MIC testing were robust across the included method variables. The modal MIC was 1 mg/L, distributions unimodal and narrow with similar geometric mean (GM)-MICs (0.745-1.072); however, susceptibility classification varied (0-28% resistance). Gradient diffusion strip testing resulted in wider and bimodal distributions for 8/9 data sets. If adopting, per manufacturer's protocol, double inoculation for the Etest method, the modal MIC increased to 2-4 mg/L and resistance rates to 45-63% versus 25-30% with the single inoculation. The EUCAST, CLSI, Etest, and MTS strip MICs correlated to the optical density of drug-free control EUCAST wells, suggesting that some isolates grew better than others and that this was associated with MIC.
  
  The EUCAST and CLSI MIC results were in close agreement, whereas the strip test showed wider and bimodal distributions with reader to reader and centre to centre variation. Our study adds to the concern for commercial MIC testing of amphotericin B against C. auris and suggests the current breakpoint leads to random susceptibility classification.
• Content Notes:
  Author manuscript
• Subjects:
  • Amphotericin B
  • Microbial Sensitivity Tests
  • Antifungal Agents
  • Humans
  • Drug Resistance, Fungal
  • Candidiasis
  • Candida auris
• Keywords:
  • Amphotericin
  • C. auris
  • Candidiasis
  • Gradient strip
  • MIC
  • Microbroth dilution
  • Reference
• Source:
  Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 2025, v. 31, no. 1
• DOI:
  https://doi.org/10.1016/j.cmi.2024.10.010
• ISSN:
  1198-743X ; 1469-0691
• Pubmed ID:
  39426481
• Pubmed Central ID:
  PMC11931498
• Document Type:
  Text
• Funding:
  CC999999/ImCDC/Intramural CDC HHSUnited States/
• Genre:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  108-112 (11 pdf pages)
• Volume:
  31
• Issue:
  1
• Download URL:
  https://stacks.cdc.gov/view/cdc/261968/cdc_261968_DS1.pdf
• File Type:
  [PDF - 321.83 KB]
• Collection(s):
  CDC Public Access
• Main Document Checksum:
  urn:sha-512:46008125a898c53b1572fd24be10b8e2a04b44f50dc111136c9fc08dd77310ca02dfab50628a9d4c5b23e1b5cf8b84da40c3bb38fb7a15fee11db3b887595c1a